Toll-like receptors: Applications to dermatologic disease

Journal of the American Academy of Dermatology

Volumn 54, Issue 6, 2006, Pages 951-983

  Kang, Sammy S W ^a   Kauls, Lynda S ^b   Gaspari, Anthony A ^c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA INTERFERON; BROPIRIMINE; IMIDAZOQUINOLINE DERIVATIVE; IMIQUIMOD; LOXORIBINE; MYELOID DIFFERENTIATION FACTOR 88; RESIQUIMOD; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9;

ACNE VULGARIS; ACTINIC KERATOSIS; ANTIGEN PRESENTATION; ATOPIC DERMATITIS; BACTERIAL INFECTION; BACTERIAL VIRULENCE; BASAL CELL CARCINOMA; CANDIDIASIS; CELLULAR IMMUNITY; CLINICAL TRIAL; CONDYLOMA; CYTOKINE PRODUCTION; DISEASE PREDISPOSITION; ENZYME DEFICIENCY; GENE EXPRESSION; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; INFECTION SENSITIVITY; INFLAMMATION; INNATE IMMUNITY; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4 DEFICIENCY; LEPROMATOUS LEPROSY; LIGAND BINDING; MYCOBACTERIUM LEPRAE; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN MOTIF; RADIATION INJURY; REVIEW; RISK ASSESSMENT; SEPSIS; SEXUALLY TRANSMITTED DISEASE; SIGNAL TRANSDUCTION; SKIN DISEASE; SYPHILIS; TREPONEMA PALLIDUM; ULTRAVIOLET RADIATION; YERSINIA;

ANIMALS; CANDIDIASIS; DERMATITIS, ATOPIC; HUMANS; SIGNAL TRANSDUCTION; SKIN; SKIN DISEASES; SKIN DISEASES, INFECTIOUS; TOLL-LIKE RECEPTORS; ULTRAVIOLET RAYS;

EID: 33646518605     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2005.05.004     Document Type: Review

References (227)

1. Medzhitov R., and Janeway C. Advances in immunology: Innate immunity. N Engl J Med 343 (2000) 338-344
2. Anderson K.V., and Nusslein-Volhard C. Information for the dorsal-ventral pattern of the Drosophila embryo is stored as maternal mRNA. Nature 311 (1984) 223-227
3. Hashimoto C., Hudson K., and Anderson K. The toll gene in Drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein. Cell 52 (1988) 269-279
4. Sims J.E., March C.J., Cosman D., Widmer M.B., MacDonald H.R., McMahan C.J., et al. cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily. Science 241 (1988) 585-589
5. Lemaitre B., Nicolas E., Michaut L., Reichhart J.M., and Hoffmann J.A. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 86 (1996) 973-983
6. Akira S., and Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 85 (2003) 85-95
7. Campos M.A., Almeida I.C., Takeuchi O., Akira S., Valente E.P., Procopio D.O., et al. Activation of Toll-like receptor-2 by glycosylphosphatidylinositol anchors from a protozoan parasite. J Immunol 167 (2001) 416-423
8. Means T.K., Lien E., Yoshimura A., Wang S., Golenbrock D.T., and Fenton M.J. The CD14 ligands lipoarabinomannan and lipopolysaccharide differ in their requirement for Toll-like receptors. J Immunol 163 (1999) 6748-6755
9. Bieback K., Lien E., Klagge I.M., Avota E., Schneider-Schaulies J., Duprex W.P., et al. Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 signaling. J Virol 76 (2002) 8729-8736
10. Compton T., Kurt-Jones E.A., Boehme C.W., Belko J., Latz E., Golenbock D.T., et al. Human cytomegalovirus activates inflammatory cytokine response via CD14 and toll-like receptor 2. J Virol 77 (2003) 4588-4596
11. Massari P., Henneke P., Ho Y., Latz E., Golenbock D.T., and Wetzer L.M. Cutting edge: immune stimulation by neisserial porins is Toll-like receptor 2 and MyD88 dependent. J Immunol 168 (2002) 1533-1537
12. Thoma-Uszynski S., Stenger S., Takeuchi O., Ochoa M.T., Engele M., Sieling P.A., et al. Induction of direct antimicrobial activity through mammalian toll-like receptors. Science 291 (2001) 1544-1547
13. Supajatura V., Ushio H., Nakao A., Akira S., Okumura K., Ra C., et al. Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. J Clin Invest 109 (2002) 1351-1359
14. Okamura Y., Watari M., Jerud E.S., Young D.W., Ishizaka S.T., Rose J., et al. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 276 (2001) 10229-10233
15. Biragyn A., Ruffini P.A., Leifer C.A., Klyushnenkova E., Shakhov A., Chertov O., et al. Toll-like receptor 4-dependent activation of dendritic cells by β-defensin 2. Science 298 (2002) 1025-1029
16. Smiley S.T., King J.A., and Hancock W.W. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol (2001) 2887-2894
17. Kurt-Jones E., Popova L., Kwinn L., Haynes L., Jones L., Tripp R., et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 1 (2000) 398-401
18. Kawasaki K., Akashi S., Shimazu R., Yoshida T., Miyake K., and Nishjima M. Mouse toll-like receptor 4-MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by Taxol. J Biol Chem 275 (2000) 2251-2254
19. Shoham S., Huang C., Chen J.-M., Golenbock D.T., and Levitz S.M. Toll-like receptor 4 mediates intracellular signaling without TNF release in response to Cryptococcus neoformans polysaccharide capsule. J Immunol 166 (2001) 4620-4626
20. Mizel S.B., Honko A.N., Moors M.A., Smith P.S., and West A.P. Induction of macrophage nitric oxide production by gram-negative flagellin involves signaling via heteromeric Toll-like receptor 5/Toll-like receptor 4 complexes. J Immunol 170 (2003) 6217-6223
21. Reiter M.J., Testerman T.L., Miller R.L., Weeks C.E., and Tomai M.A. Cytokine induction in mice by the immunomodulator imiquimod. J Leukoc Biol 13 (1994) 71-76
22. Gibson S.J., Imberston L.M., Wagner T.L., Testerman T.L., Reiter M.J., Miller R.L., et al. Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609. J Interferon Cytokine Res 15 (1995) 537-545
23. Testerman T.L., Gerster J.F., Imbertson L.M., Reiter M.J., Miller R.L., Gibson S.J., et al. Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukoc Biol 58 (1995) 365-372
24. Imberston L.M., Beaurline J.M., Couture A.M., Gibson S.J., Smith R.M., Miller R.L., et al. Cytokine induction in hairless mouse and rat skin after topical application of the immune modifiers imiquimod and S-28463. J Invest Dermatol 110 (1998) 734-739
25. Dahl M.V. Imiquimod: a cytokine inducer. J Am Acad Dermatol 47 (2002) S205-S208
26. Nagase H., Okugawa S., Ota Y., Yamaguchi M., Tomizawa H., Matsushima K., et al. Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand. J Immunol 171 (2003) 3977-3982
27. Lund J., Sato A., Akira S., Medzhitov R., and Iwasaki A. Toll-like receptor 9-mediated recognition of herpes simplex virus-2 by plasmacytoid dendritic cells. J Exp Med 198 (2003) 513-520
28. Takeuchi O., Hoshino K., Kawai T., Sanjo H., Takada H., Ogawa T., et al. Differential roles of TLR2 and TLR4 in recognition of Gram-negative and Gram-positive bacterial cell wall components. Immunity 11 (1999) 443-451
29. Schwandner R., Dziarski R., Wesche H., Rothe M., and Kirschning C.J. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor-2. J Biol Chem 274 (1999) 17406-17409
30. Aliprantis A.O., Yang R.B., Mark M.R., Suggett S., Devaux B., Radolf J.D., et al. Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science 285 (1999) 736-739
31. Takeuchi O., Kawai T., Muhlradt P.F., Morr M., Radolf J.D., Zychlinsky A., et al. Discrimination of bacterial lipoproteins by toll-like receptor 6. Int Immunol 13 (2001) 933-940
32. Takeuchi O., Sato S., Horiuchi T., Hoshino K., Takeda K., Doug Z., et al. Cutting edge: role of toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol 169 (2002) 10-14
33. Alexopoulou L., Holt A.C., Medzhitov R., and Flavell R.A. Recognition of double-stranded RNA and activation of NF-kB by toll-like receptor 3. Nature 413 (2001) 732-738
34. Poltorak A., He X., Smirnova I., Liu M.Y., Heffel C.V., Du X., et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282 (1998) 2085-2088
35. Qureshi S.T., Lariviere L., Leveque G., Clermont S., Moore K.J., Gros P., and Malo D. Endotoxin-tolerant mice have mutations in toll-like receptor 4 (Tlr4). J Exp Med 189 (1999) 615-625
36. Kurt-Jones E.A., Popova L., Kwinn L., Haynes L.M., Jones L.P., Tripp R.A., et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 1 (2000) 398-401
37. Rassa J.C., Meyers J.L., Zhang Y., Kudaravalli R., and Ross S.R. Murine retroviruses activate B cells via interaction with toll-like receptor 4. Proc Natl Acad Sci USA 99 (2002) 2281-2286
38. Vabulas R.M., Ahmad-Nejad P., da Costa C., Miethke T., Kirschning C.J., Hacker H., et al. Endocytosed HSP60 uses toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells. J Biol Chem 276 (2001) 31332-31339
39. Biragyn A., Ruffini P.A., Leifer C.A., Klyushnenkova E., Shakhov A., Chertov O., et al. Toll-like receptor 4-dependent activation of dendritic cells by β-defensin 2. Science 298 (2002) 1025-1029
40. Hayashi F., Smith K.D., Ozinsky A., Hawn T.R., Yi E.C., Goodlett D.R., et al. The innate immune response to bacterial flagellin is mediated by toll-like receptor 5. Nature 410 (2001) 1099-1103
41. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., et al. A toll-like receptor recognizes bacterial DNA. Nature 408 (2000) 740-745
42. Leadbetter E.A., Rifkin I.R., Hohlbaum A.M., Beaudette B.C., Shlomchik M.J., and Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and toll-like receptors. Nature 416 (2002) 603-607
43. Baton G.M., and Medzhitov R. Toll-like receptors and their ligands. Curr Top Microbiol Immunol 270 (2002) 81-92
44. Hemmi H., Kaisho T., Takeuchi O., Sato S., Sanjo H., Hoshino K., et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nature Immunol 3 (2002) 196-200
45. Jurk M., Heil F., Vollmer J., Schetter C., Krieg A.M., Wagner H., et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 3 (2002) 499
46. Heil F., Hemmi H., Hochrein H., Ampenberger F., Kirschning C., Akira S., et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303 (2004) 1526-1529
47. Diebold S.S., Kaisho T., Hemmi H., Akira S., and Sousa C.R. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303 (2004) 1529-1532
48. Pasare C., and Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299 (2003) 1033-1036
49. Bowie A., and O'Neill L.A. The interleukin-1 receptor/toll-like receptor superfamily: signal generators for proinflammatory interleukins and microbial products. J Leukoc Biol 67 (2000) 508
50. Xu Y., Tao X., Shen B., Horng T., Medzhitov R., Manley J.L., et al. Structural basis for signal transduction by the toll/interleukin-1 receptor domains. Nature 408 (2000) 111-115
51. Ronni T., Agarwal V., Haykinson M., Haberland M.E., Cheng G., and Smale S.T. Common interaction surfaces of the toll-like receptor 4 cytoplasmic domain stimulate multiple nuclear targets. Mol Cell Biol 23 (2003) 2543-2555
52. Baldwin Jr. A.S. The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol 14 (1996) 649
53. Ling L., Cao Z., and Goeddel D.V. NF-κB-inducing kinase activates IKK-α by phosphorylation of Ser-176. Proc Natl Acad Sci USA 95 (1998) 3792
54. Kawai T., Takeuchi O., Fujita T., Inoue J., Muhlradt P.F., Sato S., et al. Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J Immunol 167 (2001) 5887-5894
55. Sato M., Taniguchi T., and Tanaka N. The interferon system and interferon regulatory factor transcription factors: studies from gene knockout mice. Cytokine Growth Factor Rev 12 (2001) 133-142
56. Taniguchi T., and Takaoka A. The interferon-α/β system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors. Curr Opin Immunol 14 (2002) 111-116
57. Doyle S.E., Vaidya S.A., O'Connell R., Dadgostar H., Dempsey P.W., Wu T., et al. IRF3 mediates a TLR3/TLR4-specific antiviral gene program. Immunity 17 (2002) 251-263
58. Kaisho T., Takeuchi O., Kawai T., Hoshino K., and Akira S. Endotoxin-induced maturation of yD88-deficient dendritic cells. J Immunol 166 (2001) 5688-5694
59. Seki E., Tsutsui H., Nakano H., Tsuji N., Hoshino K., Adachi O., et al. Lipopolysaccharide induced IL-18 secretion from murine Kupffer cells independently of myeloid differentiation factor 88 that is critically involved in induction of production of IL-12 and IL-1β. J Immunol 166 (2001) 2651-2657
60. Horng T., Barton G.M., and Medzhitov R. TIRAP: an adaptor molecule in toll signalling. Nature Immunol 2 (2001) 835-841
61. Fitzgerald K.A., Palsson-McDermott E.M., Bowie A.G., Jeffries C.A., Mansell A.S., Brady G., et al. Mal (MyD88-adaptor-like) is required for toll-like receptor-4 signal transduction. Nature 413 (2001) 78-83
62. Schnare M., Holt A.C., Takeda K., Akira S., and Medzhitov R. Recognition of CpG DNA is mediated by signaling pathways dependent on the adaptor protein MyD88. Curr Biol 10 (2000) 1139-1142
63. Adachi O., Kawai T., Takeda K., Matsumoto M., Tsutsui H., Sakagami M., et al. Targeted disruption of the MyD88 gene results in loss of IL-1 and IL-18-mediated function. Immunity 9 (1998) 143-150
64. Yamamoto M., Sato S., Hemmi H., Sanjo H., Uematsu S., Kaisho T., et al. Essential role for TIRAP in activation of the signaling cascade shared by TLR2 and TLR4. Nature 420 (2002) 324-329
65. Horng T., Barton G.M., Flavell R.A., and Medzhitov R. The adaptor molecule TIRAP provides signaling specificity for toll-like receptors. Nature 420 (2002) 329-333
66. Yamamoto M., Sato S., Mori K., Hoshino K., Takeuchi O., Takeda K., and Akira S. Cutting edge: a novel toll/IL-1 receptor domain containing adapter that preferentially activates the IFN-β promoter in the toll-like receptor signaling. J Immunol 169 (2002) 6668-6672
67. Oshiumi H., Matsumoto M., Funami K., Akazawa T., and Seya T. TICAM-1, an adaptor molecule that participates in toll-like receptor 3-mediated interferon-β induction. Nat Immunol 4 (2003) 161
68. Yamamoto M., Sato S., Hemmi H., Hoshino K., Kaisho T., Sanjo H., et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 301 (2003) 5633
69. Sato S., Sugiyama M., Yamamoto M., Watanabe Y., Kawai T., Takeda K., et al. Toll/IL-1 receptor domain-containing adaptor inducing IFN-β (TRIF) associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates 2 distinct transcription factors, NF-κB and IFN-regulatory factor-3, in the Toll-like receptor signaling. J Immunol 171 (2003) 4304-4310
70. Fitzgerald K.A., McWhirter S.M., Faia K.L., Rowe D.C., Latz E., Golenbock D.T., et al. IKKε{lunate} and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol 4 (2003) 491
71. Strauss J.S., and Kligman A.M. The pathologic dynamics of acne vulgaris. Arch Dermatol 82 (1960) 779-791
72. Scott D.G., Cunliffe W.J., and Gowland G. Activation of complement mechanism for the inflammation in acne. Br J Dermatol 101 (1979) 315-320
73. Webster G.F., and Leyden J. Characterization of serum-independent polymorphonuclear leukocyte chemotactic factors produced by Propionibacterium acnes. Inflammation 4 (1980) 261-348
74. Vowels B.R., Yang S., and Leyden J.J. Induction of proinflammatory cytokines by a soluble factor of Propionibacterium acnes: implications for chronic inflammatory acne. Infect Immun 63 (1995) 3158-3165
75. Yang R.B., Mark M.R., Gurney A.L., and Godowski P.J. Signaling events induced by lipopolysaccharide-activated Toll-like receptor 2. J Immunol 163 (1999) 639-643
76. Kim J., Ochoa M., Krutzik S.R., Takeuchi O., Uematsu S., Legaspi A.J., et al. Activation of Toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol 169 (2002) 1535-1541
77. Vega B., Ferret C., Jomard A., and Michel S. Regulation of Toll-like receptor-2 expression by adapalene: implications for the treatment of inflammatory acne. J Invest Dermatol Abstracts 121 (2003) 156
78. Yamamura M., Uyemura K., Deans R.J., Weinberg K., Rea T.H., Bloom B.R., et al. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science 254 (1991) 277-279
79. Underhill D.M., Ozinsky A., Smith K.D., and Aderem A. Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages. Proc Natl Acad Sci USA 96 (1999) 14459-14463
80. Kang T., and Chae G. Detection of Toll-like receptor 2 (TLR2) mutation in the lepromatous leprosy patients. FEMS Immunol Med Microbiol 31 (2001) 53-58
81. Bochud P., Hawn T.R., and Aderem A. Cutting edge: a Toll-like receptor 2 polymorphism that is associated with lepromatous leprosy is unable to mediate mycobacterial signaling. J Immunol 170 (2003) 3451-3454
82. Brightbill H.D., Libraty D.H., Krutzik S.R., Yang R.B., Belisle J.T., Bleharski J.R., et al. Host defense mechanisms triggered by microbial lipoproteins through Toll-like receptors. Science 285 (1999) 732-736
83. Alexopoulou L., et al. Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice. Nat Med 8 (2002) 878-884
84. Krutzik S.R., Ochoa M.T., Sieling P.A., Uematsu S., Ng Y.W., Legaspi A., et al. Activation and regulation of Toll-like receptors 2 and 1 in human leprosy. Nat Med 9 (2003) 525-532
85. Staege H., Schaffner A., and Schneemann M. Human Toll-like receptors 2 and 4 are targets for deactivation of mononuclear phagocytes by interleukin-4. Immunol Lett 71 (2000) 1-3
86. Tramont E.C. Treponema pallidum (syphilis). In: Mandell G.L., Bennett J.E., and Dolin R. (Eds). Principles and practice of infectious diseases. 5th ed. (2000), Churchill Livingstone, New York 2474
87. Van Voorhis W.C., Barrett L.K., Koelle D.M., Nasio J.M., Plummer F.A., and Lukehart S.A. Primary and secondary syphilis lesions contain mRNA for Th1 cytokines. J Infect Dis 173 (1996) 491
88. DeOgny L., Pramanik B.C., Arndt L.L., Jones J.D., Rush J., Slaughter C.A., et al. Solid-phase synthesis of biologically active lipopeptides as analogs for spirochetal lipoproteins. Pept Res 7 (1994) 91-97
89. Sellati T.J., Bouis D.A., Kitchens R.L., Darveau R.P., Pugin J., Ulevitch R.J., et al. Treponema pallidum and Borrelia burgdorferi lipoproteins and synthetic lipopeptides activate monocytic cells via a CD14-dependent pathway distinct from that utilized by lipopolysaccharide. J Immunol 160 (1998) 5455-5464
90. Norgard M.V., Arndt L.L., Atkins D.R., Curetty L.L., Harrich D.A., and Radolf J.D. Activation of human monocytic cells by Treponema pallidum and Borrelia burgdorferi lipoproteins and synthetic lipopeptides proceeds via a pathway distinct from that of lipopolysaccharide but involves the transcriptional activator NF-κB. Infect Immun 64 (1996) 3845-3852
91. Hertz C.J., Kiertscher S.M., Godowski P.J., Bouis D.A., Norgard M.V., Roth M.D., et al. Microbial lipopeptides stimulate dendritic cell maturation via Toll-like receptor 2. J Immunol 166 (2001) 2444-2450
92. Bouis D.A., Popova T.G., Takashima A., and Norgard M.V. Dendritic cells phagocytose and are activated by Treponema pallidum. Infect Immun 69 (2001) 518-528
93. Sellati T.J., Waldrop S.L., Salazar J.C., Bergstresser P.R., Picker L.J., and Radolf J.D. The cutaneous response in humans to Treponema pallidum lipoprotein analogues involves cellular elements of both innate and adaptive immunity. J Immunol 166 (2001) 4131-4140
94. Sieling P.A., Chung W., Duong B.T., Godowski P.J., and Modlin R.L. Toll-like receptor 2 ligands as adjuvants for human Th1 responses. J Immunol 170 (2003) 194-200
95. Moors M.A., Li L., and Mizel S.B. Activation of interleukin-1 receptor-associated kinase by gram-negative flagellin. Infect Immun 69 (2001) 4424-4429
96. Underhill D.M., Ozinsky A., Hajjar A.M., Stevens A., Wilson C.B., Bassetti M., et al. The Toll-like receptor 2 is recruited to macrophage phagosome and discriminates between pathogens. Nature 401 (1999) 811-815
97. Elmets C.A., Bergstresser P.R., Tigelaar R.E., Wood P.J., and Streilein J.W. Analysis of the mechanism of unresponsiveness produced by haptens painted on skin exposed to low dose ultraviolet radiation. J Exp Med 158 (1983) 781-794
98. Toews G.B., Bergstresser P.R., and Streilein J.W. Epidermal Langerhans cell density determines whether contact hypersensitivity or unresponsiveness follows skin painting with DNFB. J Immunol 124 (1980) 445-453
99. Noonan F.P., DeFabo E.C., and Kripke M.L. Suppression of contact hypersensitivity by UV radiation and its relationship to UV-induced suppression of tumor immunity. Photochem Photobiol 34 (1981) 683-689
100. Rivas J.M., and Ullrich S.E. Systemic suppression of delayed-type hypersensitivity by supernatants from UV-irradiated keratinocytes. An essential role for keratinocyte-derived IL-10. J Immunol 149 (1992) 3865-3871
101. Yoshikawa T., Kurimoto I., and Streilein J.W. Tumor necrosis factor-alpha mediates ultraviolet light B-enhanced expression of contact hypersensitivity. Immunology 76 (1992) 254-271
102. Kock A., Schwarz T., Kirnbauer R., Urbanski A., Perry P., Ansel J.C., et al. Human keratinocytes are a source for tumor necrosis factor alpha: evidence for synthesis and release upon stimulation with endotoxin for ultraviolet light. J Exp Med 172 (1990) 1609-1614
103. Schwarz A., Grabbe S., Aragane Y., Sandkuhl K., Riemann H., Luger T.A., et al. Interleukin-12 prevents UVB-induced local immunosuppression and overcomes UVB-induced tolerance. J Invest Dermatol 106 (1996) 1187-1191
104. Lindquist S., and Craig E.A. The heat-shock proteins. Annu Rev Genet 22 (1998) 631-677
105. Vabulas R.M., Braedel S., Hilf N., Singh-Jasuja H., Herter S., Ahmad-Nejad P., et al. The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway. J Biol Chem 277 (2002) 20847-20853
106. Vabulas R.M., Ahmed-Nejad P., Ghose S., Kirschning C.J., Issels R.D., and Wagner H. HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J Biol Chem 277 (2002) 15107-15112
107. Yoshikawa T., and Streilein J.W. Genetic basis of the effects of ultraviolet light B on cutaneous immunity. Evidence that polymorphism at the TNF-α and LPS loci govern susceptibility. Immunogenetics 32 (1990) 398-405
108. Caramalho I., Lopes-Calcalho T., Oster D., Zelenay S., Haury M., and Demengeot J. Regulatory T cells selectively express Toll-like receptors and are activated by lipopolysaccharide. J Exp Med 197 (2003) 403-411
109. Epstein J.H., Kukuyama K., Reed B., and Epstein W.L. Defect in DNA synthesis in skin of patients with xeroderma pigmentosum demonstrated in vivo. Science 168 (1970) 1477-1478
110. Van Steeg H., and Kraemer K.H. Xeroderma pigmentosum and the role of UV-induced DNA damage in skin cancer. Mol Med Today 5 (1999) 86-94
111. Dupey J.M., and Lafforet D. A defect of cellular immunity in xeroderma pigmentosum. Clin Immunol Immunopathol 3 (1974) 52-58
112. Salamon T., Stojakovic M., and Bogdanovic B. Delayed hypersensitivity in xeroderma pigmentosum. Arch Derm Forsch 251 (1975) 277-280
113. Wysenbeek A.J., Weiss H., Duczyminer-Kahana M., Grunswald M.H., and Pick A.I. Immunologic alterations in xeroderma pigmentosum patients. Cancer 58 (1986) 219-221
114. Boonstra A., and Savelkoul H.F.J. The role of cytokines in ultraviolet-B induced immunosuppression. Eur Cytokine Netw 8 (1997) 117-123
115. Schwarz T. Ultraviolet radiation-induced tolerance. Allergy 54 (1999) 1252-1261
116. Miyauchi-Hashimoto H., Tanaka K., and Horio T. Enhanced inflammation and immunosuppression by ultraviolet radiation in xeroderma pigmentosum group A (XPA) model mice. J Invest Dermatol 107 (1996) 343-348
117. Gaspari A.A., Fleisher T.A., and Kraemer K.H. Impaired interferon production and natural killer cell activation in patients with the skin cancer-prone disorder, xeroderma pigmentosum. J Clin Invest 92 (1993) 1135-1142
118. Cao Z., Henzel W.J., and Gao X. IRAK: a kinase associated with the interleukin-1 receptor. Science 271 (1996) 1128-1131
119. Li S., Strelow A., Fontana E.J., and Wesche H. IRAK4: a novel member of the IRAK family with the properties of an IRAK-kinase. Proc Natl Acad Sci USA 99 (2002) 5567-5572
120. Muzio M., Ni J., Feng P., and Dixit V.M. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 278 (1997) 1612-1615
121. Wesche H., Gao X., Li X., Kirschning C.J., Stark G.R., and Cao Z. IRAK-M is a novel member of the Pelle/interleukin-1 receptor-associated kinase (IRAK) family. J Biol Chem 274 (1999) 19403-19410
122. Kobayashi K., Hernandez L.D., Galan J.E., Janeway C.A., Medzhitov R., and Flavell R.A. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 110 (2002) 191-202
123. Suzuki N., Suzuki S., Duncan G.S., Millar D.G., Wada T., Mirtsos C., et al. Severe impairment of interleukin-1 and Toll-like receptor signaling in mice lacking IRAK-4. Nature 416 (2002) 750-754
124. Picard C., Puel A., Bonnet M., Ku C., Bustamante J., Yang K., et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 299 (2003) 2076-2079
125. Medvedev A.E., Lentschat A., Kuhns D.B., Blanco J.C.G., Salkowski C., Zhang S., et al. Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections. J Exp Med 198 (2003) 521-531
126. Ulevitch R.J., and Tobias P.S. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol 13 (1995) 437
127. Nawroth P.P., Handley D., Esmon C.T., and Stern D.M. Interleukin-1 induces endothelial cell procoagulant activity while suppressing cell surface anticoagulant activity. Proc Natl Acad Sci USA 83 (1986) 3460-3464
128. Nawroth P.P., and Stern D.M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 163 (1986) 740-745
129. Moore K.L., Andreoli S.P., Esmon N.L., Esmon C.T., and Bang N.U. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 79 (1987) 124-130
130. Moore K.L., Esmon C.T., and Esmon N.L. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood 73 (1989) 159-165
131. Brandtzaeg P., Kierulf P., Gaustad P., et al. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis 159 (1989) 195-204
132. Devoe I.W., and Gilchrist J.E. Release of endotoxin in the form of cell wall blebs during in vitro growth of Neisseria meningitidis. J Exp Med 138 (1973) 1156-1167
133. Andersen B.M. Endotoxin release from Neisseria meningitidis. Relationship between key bacterial characteristics and meningococcal disease. Scand J Infect Dis Suppl 64 (1989) 1-43
134. Heppner G., and Weiss D.W. High susceptibility of strain A mice to endotoxin and endotoxin-red blood cell mixtures. J Bacteriol 90 (1965) 696-703
135. Coutinho A., Forni L., Melchers F., and Watanabe T. Genetic defect in responsiveness to the B cell mitogen lipopolysaccharide. Eur J Immunol 7 (1977) 325-328
136. Watson J., Kelly K., Largen M., and Taylor B.A. The genetic mapping of a defective LPS response gene in C3H/HeJ mice. J Immunol 120 (1978) 422-424
137. Poltorak A., Smirnova I., He X.L., Liu M.Y., van Huffel C., McNally O., et al. Genetic and physical mapping of the Lps locus- identification of the Toll-4 receptor as a candidate gene in the critical region. Blood Cells Mol Dis 24 (1998) 340-355
138. Poltorak A., Smirnova I., Clisch R., and Beutler B. Limits of a deletion spanning Tlr4 in C57BL/10ScCr mice. J Endotoxin Res 6 (2000) 51-56
139. Coutinho A., and Meo T. Genetic basis for unresponsiveness to lipopolysaccharide in C57BL/10Cr mice. Immunogenetics 7 (1978) 17-24
140. Hoshino K., Takeuchi O., Kawai T., Sanjo H., Ogawa T., Takeda Y., et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 162 (1999) 3749-3752
141. Wright S.D., Tobias P.S., Ulevitch R.J., and Ramos R.A. Lipopolysaccharide (LPS) binding protein opsonizes LPS-bearing particles for recognition by a novel receptor on macrophages. J Exp Med 170 (1989) 1231-1241
142. Shimazu R., Akashi S., Ogata H., Nagai Y., Fukudome K., Miyake K., et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 189 (1999) 1777-1782
143. Nagai Y., Akashi S., Nagafuku M., Ogata M., Iwakura Y., Akira S., et al. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol 3 (2002) 667-672
144. Wright S.D., Ramos R.A., Tobias P.S., Ulevitch R.J., and Mathison J.C. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249 (1990) 1431-1433
145. Chow J.C., Young D.W., Golenbock D.T., Christ W.J., and Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 274 (1999) 10689-10692
146. Du X., Poltorak A., Silva M., and Beutler B. Analysis of TLR4-mediated LPS signal transduction in macrophages by mutational modification of the receptor. Blood Cells Mol Dis 25 (1999) 328-338
147. Kalis C., Kanzler B., Lembo A., Poltorak A., Galanos C., and Freudenberg M.A. Toll-like receptor 4 expression levels determine the degree of LPS-susceptibility in mice. Eur J Immunol 33 (2003) 798-805
148. Bihl F., Salez L., Beaubier M., Torres D., Larivière L., Laroche L., et al. Overexpression of Toll-like receptor 4 amplifies the host response to lipopolysaccharide and provides a survival advantage in transgenic mice. J Immunol 170 (2003) 6141-6150
149. Arbour N.C., Lorenz E., Schutte B.C., Zabner J., Kline J.N., Jones M., et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 25 (2000) 187-191
150. Kline J.N., Cowden J.D., Hunninghake G.W., Schutte B.C., Watt J.L., Wohlford-Lenane C.L., et al. Variable airway responsiveness to inhaled lipopolysaccharide. Am J Respir Crit Care Med 160 (1999) 297-303
151. Lorenz E., Mira J.P., Frees K.L., and Schwartz D.A. Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med 162 (2002) 1028-1032
152. Von Aulock S., Schroder N.W.J., Gueinzius K., Traub S., Hoffmann S., Graf K., et al. Heterozygous Toll-like receptor 4 polymorphism does not influence lipopolysaccharide-induced cytokine release in human whole blood. J Infect Dis 188 (2003) 938-943
153. Ingalls R.R., Lien E., and Golenbock D.T. Differential roles of TLR2 and TLR4 in the host response to Gram-negative bacteria: lessons from a lipopolysaccharide-deficient mutant of Neisseria meningitidis. J Endotoxin Res 6 (2000) 411-415
154. Pridmore A.C., Wyllie D.H., and Abdillahi F. Steeghs L, can der Ley P, Dower SK, et al. A lipopolysaccharide-deficient mutant of Neisseria meningitidis elicits attenuated cytokine release by human macrophages and signals via Toll-like receptor (TLR) 2 but not via TLR4/MD2. J Infect Dis 183 (2001) 89-96
155. Dixon G.L., Newton P.J., Chain B.M., Katz D., Andersen S.R., Wong S., et al. Dendritic cell activation and cytokine production induced by group B Neisseria meningitidis: interleukin-12 production depends on lipopolysaccharide expression in intact bacteria. Infect Immun 69 (2001) 4351-4357
156. Ingalls R.R., Lien E., and Golenbrock D.T. Membrane-associated proteins of a lipopolysaccharide-deficient mutant of Neisseria meningitidis activate the inflammatory response through Toll-like receptor 2. Infect Immun 69 (2001) 2230
157. Massari P., Henneke P., Ho Y., Latz E., Golenbock D.T., and Wetzler L.M. Cutting edge: immune stimulation by neisserial porins is Toll-like receptor 2 and MyD88 dependent. J Immunol 168 (2002) 1533-1537
158. Al-Bader T., Christodoulides M., Heckels J.E., Holloway J., Semper A.E., and Friedmann P.S. Activation of human dendritic cells in modulated by components of the outer membranes of Neisseria meningitidis. Infect Immun 71 (2003) 5590-5597
159. Mullarkey M., Rose J.R., Bristol J., Kawata T., Kimura A., Kobayashi S., et al. Inhibition of endotoxin response by E5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J Pharm Exp Ther 304 (2003) 1093-1102
160. Leung D.Y.M. Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol 105 (2000) 860-876
161. Leyden J.E., Marples R.R., and Kligman A.M. Staphylococcus aureus in the lesions of atopic dermatitis. Br J Dermatol 90 (1974) 525-530
162. Kotzin B.L., Leung D.Y.M., Kappler J., and Marrack P. Superantigens and their potential role in human disease. Adv Immunol 54 (1993) 99-166
163. Skov L., Olsen J.V., Giorno R., Trumble A., Schlievert P.M., Baadsgaard O., et al. Application of staphylococcal enterotoxin B on normal and atopic skin induces up-regulation of T cells via a superantigenic-mediated mechanism. J Allergy Clin Immunol 105 (2000) 820-826
164. Christopher E., and Henseler T. Contrasting disease patterns in psoriasis and atopic dermatitis. Arch Dermatol Res 279 (1987) S48-S51
165. Giustizieri M.L., Mascia F., Frezzolini A., De Pita O., Chinni L.M., Giannetti A., et al. Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines. J Allergy Clin Immunol 107 (2001) 871-877
166. Cho S.H., Strickland I., Tomkinson A., Fehringer A.P., Gelfand E.W., and Leung D.Y. Preferential binding of Staphylococcus aureus to skin sites of Th2-mediated inflammation in a murine model. J Invest Dermatol 116 (2001) 658-663
167. Harder J., Bartels J., Christophers E., and Schroder J.M. A peptide antibiotic from human skin. Nature 387 (1997) 861
168. O'Neill D.A., Porter E.M., Elewaut D., Anderson G.M., Eckmann L., Ganz T., and Kagnoff M.F. Expression and regulation of the human β-defensins hBD-1 and hBD-2 in intestinal epithelium. J Immunol 163 (1999) 6718-6724
169. Ong P.Y., Ohtake T., Brandt C., Strickland I., Boguiewicz M., Ganz T., et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 347 (2002) 1151-1160
170. Birchler T., Seibl R., Buchner K., Loeliger S., Seger R., Hossle J.P., et al. Human Toll-like receptor 2 mediates induction of the antimicrobial peptide human β-defensin 2 in response to bacterial lipoprotein. Eur J Immunol 31 (2001) 3131-3137
171. Biragyn A., Ruffini P.A., Leifer C.A., Klyushnenkova E., Shakhov A., Chertov O., et al. Toll-like receptor 4-dependent activation of dendritic cells by β-defensin 2. Science 298 (2002) 1025-1029
172. Lorenz E., Mira J.P., Cornish K.L., Arbour N.C., and Schwartz D.A. A novel polymorphism in the Toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect Immun 68 (2000) 6398-6401
173. Vasquez-Torres A., and Balish E. Macrophages in resistance to candidiasis. Microbiol Mol Biol Rev 61 (1997) 170-192
174. Marodi L., Korchak H.M., and Johnston Jr. R.B. Mechanisms of host defense against Candida species. I. Phagocytosis by monocytes and monocyte-derived macrophages. J Immunol 146 (1991) 2783-2789
175. Garner R.E., Rubanowice K., Sawyer R.T., and Hudson J.A. Secretion of TNF-α by alveolar macrophages in response to Candida albicans mannan. J Leukoc Biol 55 (1996) 161-168
176. Garner RE, Hudson JA. Intravenous injection of Candida-derived mannan results in elevated tumor necrosis factor alpha levels in serum. 1996;64:4561-6.
177. DiCarlo F.J., and Fiore J.V. On the composition of zymosan. Science 127 (1957) 756
178. Ozinsky A., Underhill D.M., Fontenot J.D., Hajjar A.M., Smith K.D., Wilson C.B., et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci USA 97 (2000) 13766-13771
179. Marr K.A., Balajee A., Hawn T.R., Ozinsky A., Pham U., Akira S., et al. Differential role of MyD88 in macrophage-mediated responses to opportunistic fungal pathogens. Infect Immun 71 (2003) 5280-5286
180. Tada H., Nemoto E., Shimauchi H., Watanabe T., Mikami T., Matsumoto T., et al. Saccharomyces cerevisiae- and Candida albicans-derived mannan induced production of tumor necrosis factor alpha by human monocytes in a CD14- and Toll-like receptor 4-dependent manner. Microbiol Immunol 46 (2002) 503-512
181. Lilic D. New perspectives on the immunology of CMC. Curr Opin Infect Dis 15 (2002) 143-147
182. Lilic D., Cant A.J., Abinun M., Calvert J.E., and Spickett G.P. Chronic mucocutaneous candidiasis. I. Altered antigen stimulated IL-2, IL-4, IL-6 and IFN-γ production. Clin Exp Immunol 105 (1996) 205-212
183. Lilic D., Gravenor I., Robson N., Lammas D.A., Dysdale P., Calvert J.E., et al. Deregulated production of protective cytokines in response to Candida albicans infection in patients with chronic mucocutaneous candidiasis. Infect Immun 71 (2003) 5690-5699
184. Cenci E., Menacci A., Del Sero G., Bistoni F., and Romani L. Induction of protective Th1 responses to Candida albicans by antifungal therapy alone or in combination with an interleukin-4 antagonist. J Infect Dis 176 (1997) 217-226
185. Romani L., Mocci S., Bietta C., Lanfaloni L., Puccetti P., and Bistoni F. Th1 and Th2 cytokine secretion patterns in murine candidiasis: association of Th1 responses with acquired resistance. Infect Immun 59 (1991) 4647-4654
186. Romani L., Mencacci A., Grohmann U., Mocci S., Mosci P., Puccetti P., et al. Neutralizing antibody to interleukin 4 induces systemic production and T helper type 1-associated immunity in murine candidiasis. J Exp Med 176 (1992) 19-25
187. Netea M.G., Van der Graaf C.A.A., Vonk A.G., Verschueren I., Van der Meer J.W.M., and Kullberg B.J. The role of Toll-like receptor (TLR) 2 and TLR4 in the host defense against disseminated candidiasis. J Infect Dis 185 (2002) 1483-1489
188. Kalo-Klein A., and Witkin S.S. Prostaglandin E2 enhances and γ interferon inhibits germ tube formation in Candida albicans. Infect Immun 58 (1990) 260
189. Miller S.G., Ibe B.O., Luckett P.M., Raj J.U., and Edwards Jr. J.E. Candida albicans stimulates endothelial cell eicosanoid production. J Infect Dis 164 (1991) 928
190. Deva R., Shankaranarayanan P., Ciccoli R., and Nigam S. Candida albicans induces selectively transcriptional activation of cyclooxygenase-2 in HeLa cells: pivotal roles of toll-like receptors, p38 mitogen-activated protein kinases, and NF-kB. J Immunol 171 (2003) 3047-3055
191. Cornelis G.R., Boland A., Boyd A.P., Geuijen C., Iriarte M., Neyt C., et al. The virulence plasmid of Yersinia, an antihost genome. Microbiol Mol Biol Rev 62 (1998) 1315-1352
192. Galan J.E., and Collmer A. Type III secretion machines: bacterial devices for protein delivery into host cells. Science 284 (1999) 1322-1328
193. Aepfelbacher M., Zumbihl R., Ruckdeschel K., Jacobi C.A., Barz C., and Heesemann J. The tranquilizing injection of Yersinia proteins: a pathogen's strategy to resist host defence. Biol Chem 380 (1999) 795-802
194. Cornelis G.R. Molecular and cell biology aspects of plague. Proc Natl Acad Sci USA 97 (2000) 8778-8783
195. Sing A., Roggenkamp A., Geiger A.M., and Heesemann J. Yersinia enterocolitica evasion of the host innate immune response by V antigen-induced IL-10 production of macrophages is abrogated in IL-10-deficient mice. J Immunol 168 (2002) 1315-1321
196. Sing A., Rost D., Tvardovskaia N., Roggenkamp A., Wiedemann A., Kirschning C.J., et al. Yersinia V-antigen exploits Toll-like receptor 2 and CD14 for interleukin 10-mediated immunosuppression. J Exp Med 196 (2002) 1017-1024
197. Monack D.M., Mecsas J., Bouley D., and Falkow S. Yersinia-induced apoptosis in vivo aids in the establishment of a systemic infection of mice. J Exp Med 188 (1998) 2127-2137
198. Monack D.M., Mecsas J., Ghori N., and Falkow S. Yersinia signals macrophages to undergo apoptosis and YopJ is necessary for this cell death. Proc Natl Acad Sci USA 94 (1997) 10385-10390
199. Ruckdeschel K., Roggenkamp A., Lafont V., Mangeat P., Heesemann J., and Rouot B. Interaction of Yersinia enterocolitica with macrophages leads to macrophage cell death through apoptosis. Infect Immun 65 (1997) 4813
200. Mills S.D., Boland A., Sory M.P., van-der-Smissen P., Kerbourch C., Finlay B.B., et al. Yersinia enterocolitica induces apoptosis in macrophages by a process requiring functional type III secretion and translocation mechanisms and involving YopP, presumably acting as an effector protein. Proc Natl Acad Sci USA 94 (1997) 12638
201. Zhang Y., and Bliska J.B. Role of Toll-like receptor signaling in the apoptotic response of macrophages to Yersinia infection. Infect Immun 71 (2003) 1513-1519
202. Aliprantis A.O., Yang R.B., Weiss D.S., Godowski P., and Zychlinsky A. The apoptotic signaling pathway activated by Toll-like receptor-2. EMBO J 19 (2000) 3325-3336
203. Orth K., Palmer L.E., Bao Z.Q., Stewart S., Rudolph A.E., Bliska J.B., et al. Inhibition of the mitogen-activated protein kinase kinase superfamily by a Yersinia effector. Science 285 (1999) 1920
204. Ruckdeschel K., Mannel O., Richter K., Jacobi C.A., Trulzsch K., Rouot B., et al. Yersinia outer protein P of Yersinia enterocolitica simultaneously blocks the nuclear factor-kappa B pathway and exploits lipopolysaccharide signaling to trigger apoptosis in macrophages. J Immunol 166 (2001) 1823-1831
205. Haase R., Kirschning C.J., Sing A., Schröttner P., Fukase K., Kusumoto S., et al. A dominant role of Toll-like receptor 4 in the signaling of apoptosis in bacteria-faced macrophages. J Immunol 171 (2003) 4294-4303
206. Fenner F., Anderson D.A., Arita I., Jezek Z., and Ladnyi I.D. Smallpox and its eradication. Geneva: World Health Organization (1988)
207. Alcami A., Symons J.A., Khanna A., and Smith G.L. Poxviruses: capturing cytokines and chemokines. Semin Virol 5 (1998) 419-427
208. Smith G.L., Symons J.A., and Alcami A. Poxviruses: interfering with interferon. Semin Virol 8 (1998) 409-418
209. Bowie A., Kiss-Toth E., Symons J.A., Smith G.L., Dower S.K., and O'Neill L.A.J. A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling. Proc Natl Acad Sci USA 97 (2000) 10162-10167
210. Harte M.T., Haga I.R., Maloney G., Gray P., Reading P.C., Bartlett N.W., et al. The poxvirus protein A52R targets toll-like receptor signaling complexes to suppress host defense. J Exp Med 197 (2003) 343-351
211. Stephenson J. New therapy promising for genital herpes. J Am Med Assoc 285 (2001) 2182-2183
212. Tomai M.A., Imbertson L.M., Stanczak T.L., Tygrett L.T., and Waldschmidt T.J. The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes. Cell Immunol 203 (2000) 55-62
213. Suzuki H., Wang B., Shivji G.M., Toto P., Amerio P., Tomai M.A., et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 114 (2000) 135-141
214. Persaud A.N., Shamuelova E., Sherer D., Lou W., Singer G., Cervera C., et al. Clinical effect of imiquimod 5% cream in the treatment of actinic keratosis. J Am Acad Dermatol 47 (2002) 553-556
215. Salasche S.J., Levine N., and Morrison L. Cycle therapy of actinic keratosis of the face and scalp with 5% topical imiquimod cream: an open-label trial. J Am Acad Dermatol 47 (2002) 571-577
216. Beutner K.R., Geisse J.K., Helman D., Fox T.L., Ginkel A., and Owens M.L. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 41 (1999) 1002-1007
217. Marks R., Gebauer K., Shumack S., Amies M., Bryden J., Fox T.L., et al. The Australian Multicenter Trial Group. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 44 (2001) 807-813
218. Geisse J.K., Rich P., Pandya A., Gross K., Andres K., Ginkel A., et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 47 (2002) 390-398
219. Eedy D.J. Imiquimod: a potential role in dermatology?. Br J Dermatol 147 (2002) 1-6
220. Skinner R.B. Imiquimod. Dermatol Clin 21 (2003) 291-300
221. Gaspari A.A. Topical immune-response modifiers: mechanism of action and clinical implications. Intern Med World Rep 18 suppl (2003) 2-10
222. Gaspari A.A., and Sauder D.N. Immunotherapy of basal cell carcinoma: evolving approaches. Dermatol Surg 29 (2003) 1027-1034
223. Akira S., and Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Let 85 (2003) 85-95
224. Heil F., Ahmad-Nejad P., Hemmi H., Hochrein H., Ampenberger F., Gellert T., et al. The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol 33 (2003) 2987-2997
225. Goodman M.G. A new approach to vaccine adjuvants. Immunopotentiation by intracellular T-helper-like signals transmitted by loxoribine. Pharm Biotechnol 6 (1995) 581-609
226. Agarwala S.S., Kirkwood J.M., and Bryant J. Phase I, randomized, double-blind trial of 7-allyl-8-oxoguanosine (loxoribine) in advanced cancer. Cytokines Cell Mol Ther 6 (2000) 171-176
227. Lotzova E., Savary C.A., Khan A., and Stringfellow D.A. Stimulation of natural killer cells in two random-bred strains of athymic rats by interferon-inducing pyrimidone. J Immunol 132 (1984) 2566-2570